

## LEUKOCARE to present at multiple European Congresses

 LEUKOCARE to present at Festival of Biologics 2019, 15-17 October, Basel and at 27<sup>th</sup> annual ESGCT Congress, 22-25 October, Barcelona

## Munich, Germany, 15 October 2019

Munich-based biotechnology company LEUKOCARE announced today that it will present at two European congresses focusing on algorithm-based formulation development for therapeutic antibodies and viruses.

At the Festival of Biologics, taking place October 15-17, Dr Andreas Seidl will present a poster on "Algorithm-based Formulation Development Including a DoE Concept Enhances Formulation Development for Therapeutic Antibodies and Viruses".

At the 27<sup>th</sup> annual congress of the European Society of Gene & Cell Therapy, taking place 22-25 October, Dr Eva Reinauer will present a poster on "Effective stabilization of viral vectors in liquid using an algorithm-based development approach".

Dr Andreas Seidl and Dr Eva Reinauer will be approachable throughout the event and are looking forward to plenty of interesting discussions.

For more information, please visit:

https://www.terrapinn.com/conference/festival-of-biologics/Poster-Zone.stm

https://www.esgct.eu/Congress/Current-Congress/current-congress-programme.aspx?URL=%2fCongress%2fCurrent-Congress%2fCurrent-congress-programme.aspx&Script=%2fCongress%2fCurrent-Congress%2fCurrent-Congress%2fCurrent-congress-programme.aspx

## **About LEUKOCARE AG**

LEUKOCARE AG, located in Martinsried, Germany, is a biotech company specialized in the field of formulation development. LEUKOCARE develops superior formulations based on its pioneering SPS® formulation technology platform. The technology platform consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and, moreover, a rational development approach which employs statistical software and self-learning algorithms as well as state-of-the-art design of experiment (DoE) matrices. By utilizing these artificial intelligence elements,

LEUKOCARE is able to specifically combine excipients to generate tailored formulations that meet both the drug product requirements and needs of the relevant target product profile (TPP).

LEUKOCARE's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

## www.leukocare.com

Contact: Michael Scholl michael.scholl@leukocare.com +49 (0) 89 7801 6650